Skip to content

Study on acupuncture and moxibustion improving endometrial receptivity of patients with endometrial atypical hyperplasia and endometrial cancer after fertility preserving therapy (2) A prospective study of endometrial hyperplasia

Research and development of new technology and new scheme for preserving fertility of gynecological tumor

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2100004812
Enrollment
Unknown
Registered
2021-01-24
Start date
2021-01-25
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrial Cancer and Endometrial Atypical Hyperplasia

Interventions

Sponsors

Obstetrics and Gynecology Department, Peking University People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: (1) Aged <= 40 years, have strong desire to have children; (2) atypical hyperplasia of uterus, endometrial cancer progesterone treatment remission; (3) endometrial cancer iag1-iag2 stage, endometrial atypical hyperplasia; (4) imaging examination confirmed that the tumor was confined to the endometrium; (5) estrogen and progesterone receptor (ER, PR) were positive; (6) peripheral blood CA125; (7) no contraindication of progesterone treatment; (8) evaluation of reproductive function before treatment, no other factors of fertility disorders; (9) after complete remission, when the dominant follicle in follicular phase reached 15 mm, the endometrial thickness was less than 7.0 mm; (10) acupuncture treatment was used to improve the endometrial receptivity after preserving reproductive function; (11) informed consent was signed, and good follow-up conditions were available.

Exclusion criteria

Exclusion criteria: (1) Patients with severe medical diseases and severe impairment of liver and kidney function; (2) patients with endometrioid adenocarcinoma whose pathological stage or grade is higher than stage IA G1, or with deep myometrial invasion, cervical invasion or distant metastasis in pelvic and abdominal cavity; (3) patients with drug allergy and contraindications; (4) patients with other types of endometrial cancer or other malignant tumors of reproductive system; patients with breast cancer or other malignant tumors He can not use progesterone hormone dependent tumor; (5) require hysterectomy or other methods of treatment except conservative treatment; (6) deep vein thrombosis, stroke, myocardial infarction; (7) allergic constitution or allergic to acupuncture.

Design outcomes

Primary

MeasureTime frame
Endometrial thickness;

Secondary

MeasureTime frame
Pittsburgh sleep quality index;Endometrial morphology;Anxiety and depression assessment;Early spontaneous abortion rate;Live birth rate;Preterm birth rate;Available embryo rate;Recurrence rate;High quality embryo rate;Incidence rate of complications during pregnancy;Endometrial peristalsis;Clinical pregnancy rate;Egg rate;Embryo implantation rate;Endometrial blood flow;Relapse free survival;

Countries

China

Contacts

Public ContactQun Lu

Peking University People's Hospital

luqun1023@sina.com+86 13164242297

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026